Julia Maués: HER2-positive, HER2-low, HER2-shy
Julia Maués, Co-Founder of Grasp Cancer, shared a post by Paolo Tarantino on X and added:
“HER2-positive
HER2-low
HER2-shy (it’s there but didn’t come out in public).”
Quoting Paolo Tarantino’s post:
“HER2 is about to change again.
In DESTINY-Breast06, Trastuzumab deruxtecan significantly improved PFS in chemo-naive patients with HER2-low and HER2-ultralow MBC. OS immature. Presented at ASCO.
Press Release on AstraZeneca.”
Source: Julia Maués/X and Paolo Tarantino/X
Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School.
